Niraparib 200 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, Virginia Commonwealth University

Conditions

Advanced Solid TumorOvarian CancerProstatic Neoplasms, Castration-Resistant

Phase 1

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Active, not recruitingNCT04502602

Virginia Commonwealth UniversityAdvanced Solid Tumor, Ovarian Cancer

Start: 2020-08-24End: 2029-05-31Updated: 2025-05-04

Phase 2

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingNCT03431350

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2018-03-02End: 2026-12-31Updated: 2026-03-25

Related Papers

Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer.

2025-02-28

MP27-17 NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY

The Journal of Urology2022-04-072 citations

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).

Journal of Clinical Oncology2019-05-204 citations